Acute effects of combined vasodilation and beta-adrenoceptor blockade with prizidilol on renal function. 1983

K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi

1 The effects of a single oral dose of 600 mg of prizidilol on renal function were studied 5 to 6 h after dosing in six normal subjects and eight patients with essential hypertension. 2 Mean arterial blood pressure was reduced to 92% of the control value in normal subjects and to 75% in hypertensive patients. Heart rate increased slightly. 3 In normal subjects, effective renal plasma flow was increased to 107% of control values while glomerular filtration rate (83%), filtration fraction (79%), sodium (84%) and potassium (50%) clearances were significantly decreased. 4 In hypertensive subjects, effective renal plasma flow was increased to 120% of control values, while glomerular filtration rate (67%), filtration fraction (57%), sodium (27%) and potassium (72%) clearances were significantly decreased. 5 Plasma noradrenaline increased significantly in normal subjects (150%) and in patients (173%). Plasma renin activity, aldosterone and epinephrine levels did not change consistently. 6 The results indicate that the acute effects of prizidilol on blood pressure and renal function are more marked in hypertensive than in normotensive subjects. Prizidilol increases renal plasma flow like hydralazine and depresses glomerular filtration rate and fractional sodium excretion like endralazine. In addition to the fall in arterial pressure, efferent vasodilation and/or a specific effect on the glomerular ultrafiltration coefficient Kf may account for the striking decrease in filtration fraction.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007668 Kidney Body organ that filters blood for the secretion of URINE and that regulates ion concentrations. Kidneys
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011188 Potassium An element in the alkali group of metals with an atomic symbol K, atomic number 19, and atomic weight 39.10. It is the chief cation in the intracellular fluid of muscle and other cells. Potassium ion is a strong electrolyte that plays a significant role in the regulation of fluid volume and maintenance of the WATER-ELECTROLYTE BALANCE.
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D012039 Regional Blood Flow The flow of BLOOD through or around an organ or region of the body. Blood Flow, Regional,Blood Flows, Regional,Flow, Regional Blood,Flows, Regional Blood,Regional Blood Flows
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D005260 Female Females
D005919 Glomerular Filtration Rate The volume of water filtered out of plasma through glomerular capillary walls into Bowman's capsules per unit of time. It is considered to be equivalent to INULIN clearance. Filtration Rate, Glomerular,Filtration Rates, Glomerular,Glomerular Filtration Rates,Rate, Glomerular Filtration,Rates, Glomerular Filtration

Related Publications

K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
November 1980, Kidney international,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
May 1982, British journal of clinical pharmacology,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
February 1991, Naunyn-Schmiedeberg's archives of pharmacology,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
February 1995, Journal of clinical pharmacology,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
January 1980, Klinische Wochenschrift,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
April 1994, British journal of clinical pharmacology,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
November 1982, Clinical pharmacology and therapeutics,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
January 1981, Journal of cardiovascular pharmacology,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
March 1972, The New England journal of medicine,
K Boehringer, and P Weidmann, and L Link, and M G Bianchetti, and H Schiffl, and F C Reubi
July 1979, Klinische Wochenschrift,
Copied contents to your clipboard!